-
THRX Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
Theseus Pharmaceuticals (THRX)
Company Profile
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 47.29 mm | 47.29 mm | 47.29 mm | 47.29 mm | 47.29 mm | 47.29 mm |
Cash burn (monthly) | 316.33 k | 5.72 mm | 5.47 mm | 5.54 mm | 3.68 mm | 4.14 mm |
Cash used (since last report) | 5.07 mm | 91.71 mm | 87.65 mm | 88.87 mm | 58.92 mm | 66.30 mm |
Cash remaining | 42.22 mm | -44.41 mm | -40.35 mm | -41.57 mm | -11.62 mm | -19.01 mm |
Runway (months of cash) | 133.5 | -7.8 | -7.4 | -7.5 | -3.2 | -4.6 |
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 35.88 mm |
Total shares | 8.27 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Foresite Capital Fund V | 4.11 mm | $14.18 mm |
Tang Capital Partners | 3.26 mm | $12.99 mm |
Frazier Life Sciences Public Fund | 908.27 k | $8.72 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Feb 24 | Orbimed Advisors | Common Stock | Dispose U | Yes | No | 0 | 650,600 | 0.00 | 0 | |
14 Feb 24 | Orbimed Advisors | Common Stock | Dispose U | Yes | No | 0 | 17,063,000 | 0.00 | 0 | |
14 Feb 24 | Gordon Carl L | Common Stock | Dispose U | Yes | No | 0 | 650,600 | 0.00 | 0 | |
14 Feb 24 | Gordon Carl L | Common Stock | Dispose U | Yes | No | 0 | 17,063,000 | 0.00 | 0 | |
14 Feb 24 | Gordon Carl L | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,250 | 0.00 | 0 |
14 Feb 24 | Hayden Donald J JR | Common Stock | Dispose U | No | No | 0 | 10,000 | 0.00 | 0 | |
14 Feb 24 | Hayden Donald J JR | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,250 | 0.00 | 0 |
14 Feb 24 | Kathy Yi | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.0347 | 99,634 | 401.99 k | 0 |
14 Feb 24 | Kathy Yi | RSU Common Stock | Sale back to company | Dispose D | No | No | 0 | 3,250 | 0.00 | 0 |
14 Feb 24 | Dukes Iain D. | Common Stock | Dispose U | No | No | 0 | 388,324 | 0.00 | 0 |